The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...
The overall dry AMD market size in the US is anticipated to increase, due to the uptake of recently approved therapies, the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), ...
A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...
Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
A new approach pioneered by Aalto University scientists uses controlled warmth to trigger self-repair within retinal cells ...
No changes in protocol recommended for LUGANO and LUCIA clinical trials –– Masked safety data continues to show no safety signals, consistent ...
In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...
Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.
The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback